Stock Track | PROCEPT BioRobotics Plunges 21.73% in Post-Market on Q4 Earnings Miss

Stock Track
02/26

PROCEPT BioRobotics (PRCT) experienced a significant post-market plunge of 21.73% on Wednesday.

The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. Furthermore, the company's adjusted EBITDA loss of $19.013 million was significantly worse than the anticipated loss of $2.8 million.

CEO Larry Wood stated that the revenue shortfall was due to strategic actions including a commercial organization realignment, the elimination of end-of-quarter purchasing incentives, and a more disciplined handpiece pricing strategy. While the company reported its highest procedure volume to date and provided a revenue growth outlook of 27-33% for 2026, the substantial misses on key quarterly metrics drove the negative investor reaction.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10